A Neutralizing Antibody-inducing Peptide of the V3 Domain of Feline Immunodeficiency Virus Envelope Glycoprotein Does Not Induce Protective Immunity

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1994 Dec 1

PMID 7966629

Citations 27

Authors

S Lombardi

C Garzelli

M Pistello

C Massi

D Matteucci

F Baldinotti

G Cammarota

L Da Prato

P Bandecchi

F Tozzini

Affiliations

Soon will be listed here.

Abstract

Specific-pathogen-free cats, immunized with a 22-amino-acid synthetic peptide designated V3.3 and derived from the third variable region of the envelope glycoprotein of the Petaluma isolate of feline immunodeficiency virus (FIV), developed high antibody titers to the V3.3 peptide and to purified virus, as assayed by enzyme-linked immunoassays, as well as neutralizing antibodies, as assayed by the inhibition of syncytium formation in Crandell feline kidney cells. V3.3-immunized animals and control cats were challenged with FIV and then monitored for 12 months; V3.3 immunization failed to prevent FIV infection, as shown by virus isolation, anti-whole virus and anti-p24 immunoglobulin G antibody responses, and positive PCRs for gag and env gene fragments. Sequence analysis of the V3 region showed no evidence for the emergence of escape mutants that might have contributed to the lack of protection. The sera of the V3.3-hyperimmunized cats and two anti-V3.3 monoclonal antibodies neutralized FIV infectivity for Crandell feline kidney cells at high antibody dilutions but paradoxically failed to completely neutralize FIV infectivity at low dilutions. Moreover, following FIV challenge, V3.3-immunized animals developed a faster and higher antiviral antibody response than control cats. This was probably due to enhanced virus replication, as also suggested by quantitative PCR data.

Citing Articles

Therapeutic vaccination of koalas harbouring endogenous koala retrovirus (KoRV) improves antibody responses and reduces circulating viral load.

Olagoke O, Quigley B, Hemmatzadeh F, Tzipori G, Timms P NPJ Vaccines. 2020; 5:60.

PMID: 32699650 PMC: 7367292. DOI: 10.1038/s41541-020-0210-9.

Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.

Sahay B, Aranyos A, Mishra M, McAvoy A, Martin M, Pu R Viruses. 2019; 11(2).

PMID: 30717485 PMC: 6409633. DOI: 10.3390/v11020136.

Induction of neutralizing antibody response against koala retrovirus (KoRV) and reduction in viral load in koalas following vaccination with recombinant KoRV envelope protein.

Olagoke O, Miller D, Hemmatzadeh F, Stephenson T, Fabijan J, Hutt P NPJ Vaccines. 2018; 3:30.

PMID: 30083396 PMC: 6072795. DOI: 10.1038/s41541-018-0066-4.

FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge.

Miller C, Emanuelli M, Fink E, Musselman E, Mackie R, Troyer R NPJ Vaccines. 2018; 3:16.

PMID: 29736270 PMC: 5928050. DOI: 10.1038/s41541-018-0051-y.

Applications of the FIV Model to Study HIV Pathogenesis.

Miller C, Abdo Z, Ericsson A, Elder J, VandeWoude S Viruses. 2018; 10(4).

PMID: 29677122 PMC: 5923500. DOI: 10.3390/v10040206.

References

Pedersen N, Johnson L, Birch D, Theilen G . Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective. Vet Immunol Immunopathol. 1986; 11(2):123-48. PMC: 7125533. DOI: 10.1016/0165-2427(86)90093-0. View

Pistello M, Menzo S, Giorgi M, Da Prato L, Cammarota G, Clementi M . Competitive polymerase chain reaction for quantitating feline immunodeficiency virus load in infected cat tissues. Mol Cell Probes. 1994; 8(3):229-34. DOI: 10.1006/mcpr.1994.1032. View

Robinson Jr W, Montefiori D, MITCHELL W, Prince A, Alter H, Dreesman G . Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc Natl Acad Sci U S A. 1989; 86(12):4710-4. PMC: 287341. DOI: 10.1073/pnas.86.12.4710. View

Talbott R, Sparger E, Lovelace K, FITCH W, Pedersen N, Luciw P . Nucleotide sequence and genomic organization of feline immunodeficiency virus. Proc Natl Acad Sci U S A. 1989; 86(15):5743-7. PMC: 297706. DOI: 10.1073/pnas.86.15.5743. View

Montefiori D, Robinson Jr W, Hirsch V, Modliszewski A, MITCHELL W, Johnson P . Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques. J Virol. 1990; 64(1):113-9. PMC: 249059. DOI: 10.1128/JVI.64.1.113-119.1990. View

Egberink H, Ederveen J, Montelaro R, Pedersen N, Horzinek M, Koolen M . Intracellular proteins of feline immunodeficiency virus and their antigenic relationship with equine infectious anaemia virus proteins. J Gen Virol. 1990; 71 ( Pt 3):739-43. DOI: 10.1099/0022-1317-71-3-739. View

Phillips T, Talbott R, Lamont C, Muir S, Lovelace K, Elder J . Comparison of two host cell range variants of feline immunodeficiency virus. J Virol. 1990; 64(10):4605-13. PMC: 247944. DOI: 10.1128/JVI.64.10.4605-4613.1990. View

Fevereiro M, Roneker C, Laufs A, Tavares L, de Noronha F . Characterization of two monoclonal antibodies against feline immunodeficiency virus gag gene products and their application in an assay to evaluate neutralizing antibody activity. J Gen Virol. 1991; 72 ( Pt 3):617-22. DOI: 10.1099/0022-1317-72-3-617. View

Simmonds P, Zhang L, McOmish F, Balfe P, Ludlam C, Brown A . Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J Virol. 1991; 65(11):6266-76. PMC: 250328. DOI: 10.1128/JVI.65.11.6266-6276.1991. View

10.

Yamamoto J, Ackley C, Zochlinski H, Louie H, Pembroke E, TORTEN M . Development of IL-2-independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: importance for diagnostic reagents and vaccines. Intervirology. 1991; 32(6):361-75. DOI: 10.1159/000150220. View

11.

Morikawa S, Lutz H, Aubert A, Bishop D . Identification of conserved and variable regions in the envelope glycoprotein sequences of two feline immunodeficiency viruses isolated in Zurich, Switzerland. Virus Res. 1991; 21(1):53-63. DOI: 10.1016/0168-1702(91)90071-3. View

12.

Siebelink K, Chu I, Rimmelzwaan G, Weijer K, Osterhaus A, Bosch M . Isolation and partial characterization of infectious molecular clones of feline immunodeficiency virus obtained directly from bone marrow DNA of a naturally infected cat. J Virol. 1992; 66(2):1091-7. PMC: 240813. DOI: 10.1128/JVI.66.2.1091-1097.1992. View

13.

Avrameas A, Guillet J, Chouchane L, Moraillon A, Sonigo P, Strosberg A . Localisation of three epitopes of the env protein of feline immunodeficiency virus. Mol Immunol. 1992; 29(5):565-72. DOI: 10.1016/0161-5890(92)90192-z. View

14.

Fontenot J, Hoover E, Elder J, Montelaro R . Evaluation of feline immunodeficiency virus and feline leukemia virus transmembrane peptides for serological diagnosis. J Clin Microbiol. 1992; 30(7):1885-90. PMC: 265401. DOI: 10.1128/jcm.30.7.1885-1890.1992. View

15.

Tozzini F, Matteucci D, Bandecchi P, Baldinotti F, Poli A, Pistello M . Simple in vitro methods for titrating feline immunodeficiency virus (FIV) and FIV neutralizing antibodies. J Virol Methods. 1992; 37(3):241-52. DOI: 10.1016/0166-0934(92)90026-a. View

16.

Pancino G, Chappey C, Saurin W, Sonigo P . B epitopes and selection pressures in feline immunodeficiency virus envelope glycoproteins. J Virol. 1993; 67(2):664-72. PMC: 237417. DOI: 10.1128/JVI.67.2.664-672.1993. View

17.

Pancino G, Fossati I, Chappey C, Castelot S, Hurtrel B, Moraillon A . Structure and variations of feline immunodeficiency virus envelope glycoproteins. Virology. 1993; 192(2):659-62. DOI: 10.1006/viro.1993.1083. View

18.

Hosie M, Osborne R, Reid G, Neil J, Jarrett O . Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol. 1992; 35(1-2):191-7. PMC: 7119648. DOI: 10.1016/0165-2427(92)90131-9. View

19.

Siebelink K, Rimmelzwaan G, Bosch M, Meloen R, Osterhaus A . A single amino acid substitution in hypervariable region 5 of the envelope protein of feline immunodeficiency virus allows escape from virus neutralization. J Virol. 1993; 67(4):2202-8. PMC: 240339. DOI: 10.1128/JVI.67.4.2202-2208.1993. View

20.

Matteucci D, Baldinotti F, Mazzetti P, Pistello M, Bandecchi P, Ghilarducci R . Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction. J Clin Microbiol. 1993; 31(3):494-501. PMC: 262808. DOI: 10.1128/jcm.31.3.494-501.1993. View